Lonza Group AG is a Swiss multinational manufacturing company based in Basel, specializing in contract development and manufacturing services for the pharmaceutical, biotechnology, and nutrition sectors. Founded in 1897, Lonza has evolved from its origins in hydroelectric power to become a leader in biopharmaceutical manufacturing, operating over thirty development and manufacturing sites worldwide.
As a pure-play contract development and manufacturing organization (CDMO), Lonza offers a wide range of services, including biologics manufacturing, small molecules production, bioconjugates, and cell and gene therapies. The company also provides drug product services and detection systems for the bioscience sector. Lonza has established significant partnerships with major pharmaceutical companies, including a notable collaboration with Moderna for the production of its COVID-19 vaccine. With a strong market position, Lonza plays a crucial role in the growth of outsourced drug manufacturing and the development of innovative therapies.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Operator of advanced biopharmaceutical manufacturing company intended to change the way medicine is produced. The company offers a broad mix of customized manufacturing capabilities to serve the requirements of biopharmaceuticals at all stages of the drug development process - from pre-clinical development to commercial supply, thereby offering clients customized and scalable processes, with high-quality and regulatory capability, facilities for complex and novel medicines.
Manufacturer of pharmaceutical products and services intended to serve international health organizations, and public sectors. The company supplies several essential and lifesaving vaccines and pharmaceuticals and is committed to the prevention of hazards, risks and negative environmental impacts while developing, manufacturing, storing, handling and distributing its products, thereby enhancing mankind's ability to predict illness.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.